EP4566629A3 - Verwendung von niedervolumigem plasmaaustausch zur behandlung von morbus alzheimer in frühen und mittleren phasen - Google Patents

Verwendung von niedervolumigem plasmaaustausch zur behandlung von morbus alzheimer in frühen und mittleren phasen

Info

Publication number
EP4566629A3
EP4566629A3 EP25170160.3A EP25170160A EP4566629A3 EP 4566629 A3 EP4566629 A3 EP 4566629A3 EP 25170160 A EP25170160 A EP 25170160A EP 4566629 A3 EP4566629 A3 EP 4566629A3
Authority
EP
European Patent Office
Prior art keywords
disease
treatment
alzheimer
early
plasma exchange
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25170160.3A
Other languages
English (en)
French (fr)
Other versions
EP4566629A2 (de
Inventor
Victor Grifols Roura
Antonio Manuel Paez Regadera
Laura Nuñez Domenech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Worldwide Operations Ltd
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of EP4566629A2 publication Critical patent/EP4566629A2/de
Publication of EP4566629A3 publication Critical patent/EP4566629A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP25170160.3A 2018-10-25 2019-10-23 Verwendung von niedervolumigem plasmaaustausch zur behandlung von morbus alzheimer in frühen und mittleren phasen Pending EP4566629A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18202720.1A EP3643319A1 (de) 2018-10-25 2018-10-25 Verwendung eines niedervolumigen plasmaaustausches zur behandlung von morbus alzheimer in frühen und mittleren stadien
EP19820861.3A EP3871686B1 (de) 2018-10-25 2019-10-23 Verwendung eines plasmaaustauschs mit niedrigem volumen zur behandlung von morbus alzheimer im mittleren stadium
PCT/IB2019/001145 WO2020084346A1 (es) 2018-10-25 2019-10-23 Uso de recambio plasmático de bajo volumen para el tratamiento de la enfermedad de alzheímer en etapas temprana y moderada

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP19820861.3A Division EP3871686B1 (de) 2018-10-25 2019-10-23 Verwendung eines plasmaaustauschs mit niedrigem volumen zur behandlung von morbus alzheimer im mittleren stadium
EP19820861.3A Division-Into EP3871686B1 (de) 2018-10-25 2019-10-23 Verwendung eines plasmaaustauschs mit niedrigem volumen zur behandlung von morbus alzheimer im mittleren stadium

Publications (2)

Publication Number Publication Date
EP4566629A2 EP4566629A2 (de) 2025-06-11
EP4566629A3 true EP4566629A3 (de) 2025-08-13

Family

ID=64308472

Family Applications (3)

Application Number Title Priority Date Filing Date
EP18202720.1A Withdrawn EP3643319A1 (de) 2018-10-25 2018-10-25 Verwendung eines niedervolumigen plasmaaustausches zur behandlung von morbus alzheimer in frühen und mittleren stadien
EP25170160.3A Pending EP4566629A3 (de) 2018-10-25 2019-10-23 Verwendung von niedervolumigem plasmaaustausch zur behandlung von morbus alzheimer in frühen und mittleren phasen
EP19820861.3A Active EP3871686B1 (de) 2018-10-25 2019-10-23 Verwendung eines plasmaaustauschs mit niedrigem volumen zur behandlung von morbus alzheimer im mittleren stadium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18202720.1A Withdrawn EP3643319A1 (de) 2018-10-25 2018-10-25 Verwendung eines niedervolumigen plasmaaustausches zur behandlung von morbus alzheimer in frühen und mittleren stadien

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19820861.3A Active EP3871686B1 (de) 2018-10-25 2019-10-23 Verwendung eines plasmaaustauschs mit niedrigem volumen zur behandlung von morbus alzheimer im mittleren stadium

Country Status (17)

Country Link
US (2) US20220047680A1 (de)
EP (3) EP3643319A1 (de)
JP (1) JP7631189B2 (de)
KR (1) KR20210086604A (de)
CN (1) CN112672756A (de)
AR (1) AR116918A1 (de)
AU (1) AU2019365514B2 (de)
BR (1) BR112021004473A2 (de)
CA (1) CA3112452A1 (de)
CL (1) CL2021000593A1 (de)
ES (1) ES3036497T3 (de)
IL (1) IL281395A (de)
MX (1) MX2021002936A (de)
SG (1) SG11202102437PA (de)
TW (1) TWI831851B (de)
UY (1) UY38426A (de)
WO (1) WO2020084346A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
JP2024516390A (ja) * 2021-04-30 2024-04-15 グリフォルス・ワールドワイド・オペレーションズ・リミテッド 認知機能障害を処置するための治療的血漿交換及び低体積血漿交換の使用
CA3257817A1 (en) 2022-05-31 2023-12-07 Circulate Health, Inc. PLASMAPHERESIS COMPOSITIONS AND PROCESSES
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
EP3137097B1 (de) * 2014-04-29 2023-06-21 ADvantage Therapeutics, Inc. Behandlung und prävention von alzheimer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOADA ET AL: "Changes in cognitive status of Alzheimer's disease patients treated with plasma exchange and replacement with human albumin plus immunoglobulin. Interim results of the AMBAR trial.", ALZHEIMER DEMENTIA, vol. 12, 2016 - 2016, pages P419 - P420, XP002790387 *
BOADA M; RAMOS-FERN�NDEZ E; GUIVERNAU B; MU�OZ F J; COSTA M; ORTIZ A M; JORQUERA J I; N��EZ L; TORRES M; P�EZ A: "Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.", NEUROLOGIA, vol. 71, no. 7, 9 July 2014 (2014-07-09) - 9 July 2014 (2014-07-09), pages 473 - 481, XP002790386 *

Also Published As

Publication number Publication date
TWI831851B (zh) 2024-02-11
EP3871686A1 (de) 2021-09-01
SG11202102437PA (en) 2021-04-29
EP3643319A1 (de) 2020-04-29
TW202031286A (zh) 2020-09-01
JP7631189B2 (ja) 2025-02-18
CL2021000593A1 (es) 2021-07-30
BR112021004473A2 (pt) 2021-05-25
EP4566629A2 (de) 2025-06-11
UY38426A (es) 2020-03-31
US20220047680A1 (en) 2022-02-17
WO2020084346A1 (es) 2020-04-30
AU2019365514A1 (en) 2021-04-08
US20240115665A1 (en) 2024-04-11
JP2022503682A (ja) 2022-01-12
EP3871686B1 (de) 2025-07-09
AU2019365514B2 (en) 2025-04-10
KR20210086604A (ko) 2021-07-08
AR116918A1 (es) 2021-06-30
ES3036497T3 (en) 2025-09-19
CA3112452A1 (en) 2020-04-30
IL281395A (en) 2021-04-29
MX2021002936A (es) 2021-06-15
CN112672756A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
EP4566629A3 (de) Verwendung von niedervolumigem plasmaaustausch zur behandlung von morbus alzheimer in frühen und mittleren phasen
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
PH12018502634A1 (en) Topical compositions of apremilast
MX2023010326A (es) Inhibidores de atf6 y sus usos.
MX2021004431A (es) Procesos novedosos.
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
EP4566675A3 (de) Heterocyclische verbindungen als immunmodulatoren
EP4374851A3 (de) Ophthalmische zusammensetzung zur behandlung von trockenem auge
EP4233910A3 (de) Verfahren zur behandlung von cholestatischen erkrankungen
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
EP4684836A3 (de) Kombinationen von lsd1-inhibitoren zur verwendung bei der behandlung neoplastischer erkrankungen
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
EP4364801A3 (de) Optimierte dosierung von diaminophenothiazinen in populationen
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
GEP20257840B (en) Tyk2 pseudokinase ligands
MX2022000712A (es) Moduladores de nlrp3.
EP4410312A3 (de) Topische cyclosporinhaltige formulierungen und verwendungen davon
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
PH12022552447A1 (en) Nlrp3 modulators
PH12020551841A1 (en) Stable pharmaceutical formulation
EP4585213A3 (de) Amlodipinformulierungen
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3871686

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0045060000

Ipc: A61K0038380000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_27889/2025

Effective date: 20250611

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/38 20060101AFI20250704BHEP

Ipc: A61K 45/06 20060101ALI20250704BHEP

Ipc: A61P 25/28 20060101ALI20250704BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260209